Table 2.
Baseline variables of those fulfilling the simplified remission criteria and those not fulfilling the criteria at year 2
| Total, N = 92 | Fulfilling criteria, n = 40 | Not fulfilling criteria, n = 52 | OR (95% CI) a | P value | |
|---|---|---|---|---|---|
| Age, median (IQR), y | 63 (55–71) | 66 (55–71) | 62 (54–71) | 1.01 (0.98–1.05) | 0.46 |
| Male, n (%) | 89 (97) | 38 (95) | 51 (98) | 0.37 (0.03–4.26) | 0.43 |
| Ethnicity, n (%) | |||||
| Māori | 8 (9) | 3 (8) | 5 (10) | 0.76 (0.17–3.40) | 0.72 |
| NZ European | 62 (67) | 31 (78) | 31 (60) | 2.33 (0.92–5.89) | 0.73 |
| Other | 8 (9) | 4 (10) | 4 (8) | 1.33 (0.31–5.69) | 0.70 |
| Pacific peoples | 14 (15) | 2 (5) | 12 (23) | 0.18 (0.04–0.84) | 0.03 |
| Age of first gout attack, median (IQR) | 37 (30–52) | 40 (30–55) | 35 (29–51) | 1.01 (0.98–1.04) | 0.58 |
| Disease duration, median (IQR) | 20 (9–31) | 19 (8–25) | 20 (9–32) | 0.99 (0.96–1.02) | 0.59 |
| Body mass index, median (IQR) | 31 (27–35) | 28 (26–32) | 32 (28–37) | 0.88 (0.81–0.96) | 0.005 |
| Baseline serum urate, median (IQR), mmol/L | 0.35 (0.31–0.40) | 0.35 (0.30–0.40) | 0.35 (0.32–0.40) | 0.03 (0.00–5.33) | 0.19 |
| Baseline subcutaneous tophus count, median (IQR) | 2 (0–4) | 1 (0–4) | 2 (1–6) | 0.93 (0.85–1.01) | 0.10 |
| Number of gout flares in preceding 3 mo, median (IQR) | 1 (0–2) | 0 (0–1) | 1 (0–3) | 0.77 (0.60–0.98) | 0.04 |
| Baseline pain, median (IQR), 10‐cm VAS | 0.35 (0.00–2.15) | 0.20 (0.00–1.65) | 0.48 (0.00–3.10) | 0.86 (0.71–1.06) | 0.15 |
| Baseline patient global assessment, median (IQR), 10‐cm VAS | 2.00 (1.00–3.50) | 2.00 (1.00–3.00) | 2.50 (1.00–4.00) | 0.95 (0.80–1.13) | 0.55 |
| Baseline serum creatinine, median (IQR), μmol/L | 91 (82–105) | 93 (82–108) | 91 (82–104) | 1.01 (0.99–1.03) | 0.39 |
| Baseline creatinine clearance, median (IQR), mL/min | 72 (61–87) | 71 (58–82) | 74 (63–89) | 0.99 (0.96–1.01) | 0.20 |
| Comorbidities, n (%) | |||||
| Type 2 diabetes | 6 (7) | 2 (5) | 4 (7.7) | 0.63 (0.11–3.63) | 0.61 |
| High cholesterol | 40 (43) | 18 (45) | 22 (42) | 1.12 (0.49–2.56) | 0.80 |
| Hypertension | 45 (49) | 18 (45) | 27 (51.9) | 0.76 (0.33–1.73) | 0.51 |
| Cardiovascular disease | 11 (12) | 6 (15) | 5 (9.6) | 1.66 (0.47–5.88) | 0.43 |
| Kidney disease | 18 (20) | 8 (20) | 10 (19) | 1.05 (0.37–2.96) | 0.93 |
| Baseline DECT MSU crystal volume, median (IQR), cm3 | 0.12 (0.05–0.95) | 0.06 (0.03–0.11) | 0.37 (0.08–2.17) | 0.54 (0.40–0.73) | <0.001 |
| Baseline radiographic damage score, median (IQR) | 5.70 (2.50–11.75) | 5.196 (2.19–12.06) | 6.00 (2.50–11.75) | 1.00 (0.95–1.04) | 0.89 |
| Baseline CT erosion score, median (IQR) | 7.00 (4.00–13.50) | 6.25 (3.00–12.00) | 7.25 (5.00–15.50) | 0.96 (0.90–1.02) | 0.21 |
| Randomization group, n (%) | |||||
| Intensive target group b | 46 (50) | 20 (50) | 26 (50) | 1.00 (0.44–2.28) | >0.99 |
*
CI, confidence interval; CT, computed tomography; DECT, dual‐energy computed tomography; IQR, interquartile range; MSU, monosodium urate; NZ, New Zealand; OR, odds ratio; VAS, visual analog scale.
a
Continuous measures were analyzed as the odds of a one‐unit difference.
b
Standard target group set as reference.